2024-03-28T14:46:43Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00009789
2022-12-15T03:43:43Z
453:456
471:537:538:946
3 髄芽腫の治療成績と今後の展望(Child Cancer Survivors : 長期予後とQOLの改善に向けて,第654回新潟医学会)
3 髄芽腫の治療成績と今後の展望(Child Cancer Survivors : 長期予後とQOLの改善に向けて,第654回新潟医学会)
Clinical Outcome and Perspective in Future for Treatment of Medulloblastoma (Child Cancer Survivors : Long-Term Outcome and for a Better QOL Engagement)
西山, 健一
吉村, 淳一
藤井, 幸彦
medulloblastoma
radiotherapy
chemotherapy
Clinical outcome of treatment for 64 patents with medulloblastoma were analyzed and our current strategies with historical comparisons were discussed. From 1992 to present, 25 patients were treated with our current regimen with maximum resection, receiving 36Gy of cerebrospinal irradiation (CSI) with a posterior fossa boost of 18-24Gy starting within two weeks after surgery. The 5-year overall survival was 79.2%. This is relatively high, however the late radiation injury of cognitive dysfunctions and endocrinological sequelae were observed in younger children. We consider that reducing the dose of CSI to 24Gy with induction of adjuvant chemotherapy in average-risk patients is considered to be appropriate for preventing late radiation injury and improving the survival rate.
新潟医学会
2012-02
jpn
departmental bulletin paper
http://hdl.handle.net/10191/31404
https://niigata-u.repo.nii.ac.jp/records/9789
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
126
2
71
75
https://niigata-u.repo.nii.ac.jp/record/9789/files/126(2)_71-75.pdf
application/pdf
2.0 MB
2019-08-06